The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|17|1|30-41

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.17, Iss.1, 2016-01, pp. : 30-41

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted therapy in acute myeloid leukaemia: current status and future directions

By Stapnes Camilla   Gjertsen Bjørn Tore   Reikvam Håkon   Bruserud Øystein  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 433-455

Informa Healthcare

Access to resources Recommend Favorite

Management of acute myeloid leukaemia

By Rule Simon   Poirer Veronique   Singer Charles  

Clinical Medicine, Vol. 1, Iss. 4, 2001-07 ,pp. : 313-316

Royal College Of Physicians

Access to resources Recommend Favorite

Doxorubicin/etoposide/ifosfamide: Therapy-related acute myeloid leukaemia: case report

By  

Reactions Weekly, Vol. 1, Iss. 1287, 2010-01 ,pp. : 18-19

Adis International

Access to resources Recommend Favorite

Azacitidine: A Review of its Use in the Management of Myelodysplastic Syndromes/Acute Myeloid Leukaemia

By Keating Gillian M.  

Drugs, Vol. 72, Iss. 8, 2012-05 ,pp. : 1111-1136

Adis International

Access to resources Recommend Favorite

Gemtuzumab Ozogamicin: A Review of its Use in Acute Myeloid Leukaemia

By Fenton Caroline   Perry Caroline M.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2405-2427

Adis International

Access to resources Recommend Favorite